Agios Pharmaceuticals Inc.

54.69-0.3500-0.64%Vol 1.12M1Y Perf 27.16%
Apr 16th, 2021 16:00 DELAYED
BID50.24 ASK55.04
Open54.79 Previous Close55.04
Pre-Market- After-Market54.69
 - -  - -%
Target Price
63.38 
Analyst Rating
Strong Buy 1.40
Potential %
15.89 
Finscreener Ranking
★★★★     53.42
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.58
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     58.54
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap3.82B 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
83.98 
Earnings Date
29th Apr 2021

Today's Price Range

53.9155.98

52W Range

32.4758.93

5 Year PE Ratio Range

-10.70-8.30

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
3.64%
1 Month
6.05%
3 Months
19.75%
6 Months
52.47%
1 Year
27.16%
3 Years
-37.04%
5 Years
12.58%
10 Years
-

TickerPriceChg.Chg.%
AGIO54.69-0.3500-0.64
AAPL134.16-0.3400-0.25
GOOG2 297.761.10000.05
MSFT260.741.24000.48
XOM56.66-0.3200-0.56
WFC43.841.60003.79
JNJ162.241.85001.15
FB306.18-1.6400-0.53
GE13.39-0.1600-1.18
JPM153.301.13000.74
Financial StrengthValueIndustryS&P 500US Markets
6.30
6.70
0.20
0.26
-17.40
Leverage Ratio 1.90
ProfitabilityValueIndustryS&P 500US Markets
98.60
-172.20
-167.40
-378.50
-
RevenueValueIndustryS&P 500US Markets
116.10M
1.66
64.95
28.52
Earnings HistoryEstimateReportedSurprise %
Q04 2020-1.41-1.410.00
Q03 2020-1.40-1.43-2.14
Q02 2020-1.42-1.317.75
Q01 2020-1.70-0.5965.29
Q04 2019-1.78-1.6010.11
Q03 2019-1.85-1.812.16
Q02 2019-1.73-1.87-8.09
Q01 2019-1.74-1.598.62
Earnings Per EndEstimateRevision %Trend
3/2021 QR-1.297.86Positive
6/2021 QR-1.453.33Positive
12/2021 FY-5.794.61Positive
12/2022 FY-6.73-8.90Negative
Next Report Date29th Apr 2021
Estimated EPS Next Report-1.23
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.12M
Shares Outstanding69.81M
Trades Count11.21K
Dollar Volume36.46M
Avg. Volume776.00K
Avg. Weekly Volume772.20K
Avg. Monthly Volume828.83K
Avg. Quarterly Volume771.59K

Agios Pharmaceuticals Inc. (NASDAQ: AGIO) stock closed at 54.69 per share at the end of the most recent trading day (a -0.64% change compared to the prior day closing price) with a volume of 1.12M shares and market capitalization of 3.82B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 562 people. Agios Pharmaceuticals Inc. CEO is Jacqualyn A. Fouse.

The one-year performance of Agios Pharmaceuticals Inc. stock is 27.16%, while year-to-date (YTD) performance is 26.22%. AGIO stock has a five-year performance of 12.58%. Its 52-week range is between 32.47 and 58.93, which gives AGIO stock a 52-week price range ratio of 83.98%

Agios Pharmaceuticals Inc. currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 9.22, a price-to-sale (PS) ratio of 31.41, a price to cashflow ratio of 50.40, a PEG ratio of 2.32, a ROA of -35.92%, a ROC of -59.31% and a ROE of -59.69%. The company’s profit margin is -%, its EBITDA margin is -167.40%, and its revenue ttm is $116.10 Million , which makes it $1.66 revenue per share.

Of the last four earnings reports from Agios Pharmaceuticals Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.23 for the next earnings report. Agios Pharmaceuticals Inc.’s next earnings report date is 29th Apr 2021.

The consensus rating of Wall Street analysts for Agios Pharmaceuticals Inc. is Strong Buy (1.4), with a target price of $63.38, which is +15.89% compared to the current price. The earnings rating for Agios Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Agios Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Agios Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.59, ATR14 : 2.82, CCI20 : 118.12, Chaikin Money Flow : 0.06, MACD : 0.84, Money Flow Index : 54.99, ROC : 11.05, RSI : 52.91, STOCH (14,3) : 86.56, STOCH RSI : 0.87, UO : 52.46, Williams %R : -13.44), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Agios Pharmaceuticals Inc. in the last 12-months were: Andrew Hirsch (Option Excercise at a value of $0), Carman Alenson (Option Excercise at a value of $0), Carman Alenson (Sold 250 shares of value $9 983 ), Christopher Bowden (Option Excercise at a value of $125 978), Christopher Bowden (Sold 3 583 shares of value $179 200 ), Darrin Miles (Option Excercise at a value of $0), Darrin Miles (Sold 2 700 shares of value $129 868 ), David P. Schenkein (Option Excercise at a value of $0), David Scadden (Option Excercise at a value of $0), Ian T. Clark (Option Excercise at a value of $0), Jacqualyn A. Fouse (Option Excercise at a value of $0), John M. Maraganore (Option Excercise at a value of $0), Kaye I. Foster-Cheek (Option Excercise at a value of $0), Maykin Ho (Option Excercise at a value of $0), Paul J. Clancy (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (80.00 %)
8 (80.00 %)
8 (80.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (20.00 %)
2 (20.00 %)
2 (20.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.40
Strong Buy
1.40
Strong Buy
1.40

Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

CEO: Jacqualyn A. Fouse

Telephone: +1 617 649-8600

Address: 88 Sidney Street, Cambridge 02139, MA, US

Number of employees: 562

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

58%42%

Bearish Bullish

56%44%

Bearish Bullish

65%35%

News

Stocktwits